InvestorsHub Logo
icon url

bfost

11/18/18 11:49 AM

#160755 RE: IgnoranceIsBliss #160737

Circuitcity. Yes AMRN is definitely looking at epa levels and aa/epa ratio. This was asked at the investor conference. The science officer said they are very interested in these and aware of commercially available testing and possibly use of lab testing in predicting best patient candidates.
icon url

circuitcity

11/18/18 12:34 PM

#160765 RE: IgnoranceIsBliss #160737

TTE, your action is even faster than my mind, unbelievable, thanks a lot!
icon url

SonamKapoor

11/18/18 3:18 PM

#160793 RE: IgnoranceIsBliss #160737

TTE: Yes, anti-thrombotics have been a focus of Japan's race to the North Pole for awhile.

Dr. Aizan Hirai with some background -

















icon url

SonamKapoor

11/18/18 3:37 PM

#160794 RE: IgnoranceIsBliss #160737

TTE: more on Japan-

Lots of historical studies in Japan on EPA EE in clinical drug testing.


Japan marketshare growth for EPA EE


Pure EPA EE proof after refining/concentrating


EPA in vials

icon url

SonamKapoor

11/18/18 4:34 PM

#160801 RE: IgnoranceIsBliss #160737

JFMCRR: thanks for the yogurt trick.
--------
Deepak Bhatt and others - anti-thrombotic effects.

In 2012 - Dr. Bhatt and "novel therapies"


More history:





Oh, is this part of the answer to my question which was why Japan would be intensely focused on the anti-thrombotic effects of EPA EE. I wonder if its because the two populations are different as below?





Very interesting.